The Manufacturers Life Insurance Company Purchases Shares of 38,172 Repligen Corporation $RGEN

The Manufacturers Life Insurance Company acquired a new position in shares of Repligen Corporation (NASDAQ:RGEN) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 38,172 shares of the biotechnology company’s stock, valued at approximately $5,208,000. The Manufacturers Life Insurance Company owned about 0.07% of Repligen at the end of the most recent quarter.

A number of other large investors have also recently made changes to their positions in the business. AQR Capital Management LLC acquired a new position in shares of Repligen during the first quarter valued at about $262,000. Jones Financial Companies Lllp lifted its position in Repligen by 3,850.6% in the 1st quarter. Jones Financial Companies Lllp now owns 6,400 shares of the biotechnology company’s stock valued at $814,000 after acquiring an additional 6,238 shares in the last quarter. Goldman Sachs Group Inc. lifted its position in Repligen by 16.8% in the 1st quarter. Goldman Sachs Group Inc. now owns 141,994 shares of the biotechnology company’s stock valued at $18,067,000 after acquiring an additional 20,375 shares in the last quarter. Bank of Nova Scotia increased its holdings in Repligen by 88.0% during the 2nd quarter. Bank of Nova Scotia now owns 31,747 shares of the biotechnology company’s stock worth $3,951,000 after purchasing an additional 14,860 shares in the last quarter. Finally, Daiwa Securities Group Inc. raised its stake in shares of Repligen by 29.7% in the second quarter. Daiwa Securities Group Inc. now owns 31,194 shares of the biotechnology company’s stock worth $3,880,000 after purchasing an additional 7,148 shares during the last quarter. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on RGEN. Jefferies Financial Group reiterated a “hold” rating and set a $142.00 price target on shares of Repligen in a report on Tuesday, May 5th. Barclays upped their price objective on shares of Repligen from $145.00 to $160.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Evercore reiterated an “outperform” rating and issued a $160.00 price objective on shares of Repligen in a research note on Monday, July 6th. HSBC dropped their target price on shares of Repligen from $170.00 to $150.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Royal Bank Of Canada started coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. Three analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and a consensus target price of $166.43.

Repligen Price Performance

RGEN opened at $180.98 on Tuesday. The company has a market capitalization of $10.21 billion, a price-to-earnings ratio of 247.92, a PEG ratio of 3.22 and a beta of 1.03. The company has a quick ratio of 7.64, a current ratio of 9.05 and a debt-to-equity ratio of 0.26. The firm has a 50-day moving average price of $153.08 and a 200-day moving average price of $133.28. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73.

Repligen (NASDAQ:RGEN) last announced its quarterly earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The company had revenue of $204.13 million for the quarter, compared to analysts’ expectations of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. Repligen’s revenue was up 11.9% compared to the same quarter last year. During the same period in the prior year, the company posted $0.26 EPS. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. Equities analysts expect that Repligen Corporation will post 2.06 EPS for the current year.

Insider Activity

In other Repligen news, CFO Jason K. Garland sold 733 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the sale, the chief financial officer owned 19,359 shares in the company, valued at $2,807,055. This represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. 0.60% of the stock is currently owned by corporate insiders.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.